Latest Conference Articles

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

Dr. Martin explains the connection between inclusive cardiology technology and patient care and confidence.

In part 2 of an interview with HCPLive, Ty Gluckman, MD discusses both the advantages and disadvantages of technology replacing traditional care.

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Advancements in technology and the availability of resources for patients and doctors alike could mean a bright future for cardiology research.

Ty Gluckman, MD speaks on the use of medical technology, including wearables and and telemedicine, and the growing importance of mobile health.

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

Dr. Taub speaks on the technology-based advancements in cardiovascular care and socioeconomic status can affect a patient’s diet and access to care.

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Dr. Pam Taub speaks on the misconceptions of cardiac rehabilitation and other lifestyle approaches recommended for patients with cardiovascular diseases.

Peter Toth, MD, discusses the movement towards new agents in treatment of lipid management.

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

The virtual sessions will cover a litany of topics in the greater spectrum of cardiovascular disease prevention and care.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.

A longer time spent in hypoglycemia over a 24-hour period was associated with disrupted sleep among children with type 1 diabetes.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.